Skip to main content
Year archive

EMYRIA LIMITED — 2023 filings

All 98 regulatory filings released by EMYRIA LIMITED (EMD) in 2023, sourced directly from the official regulator.

98 Filings
2023 Period
2023 filings (98)
Filing Released Lang
Notification of cessation of securities - EMD 5 pages 25.3KB
Share Issue/Capital Change
2023-11-26 English
Change in Substantial Holding 2 pages 339.3KB
Major Shareholding Notification
2023-11-26 English
Final Director's Interest Notice - S. Washer 2 pages 169.3KB
Director's Dealing
2023-11-21 English
Initial Director's Interest Notice - G. Hutchinson 2 pages 190.0KB
Director's Dealing
2023-11-21 English
Application for quotation of securities - EMD 9 pages 33.1KB
Capital/Financing Update
2023-11-20 English
Eminent Healthcare Leader New Independent Non-Exec Chair 4 pages 917.8KB
Board/Management Information
2023-11-20 English
Results of Annual General Meeting 2 pages 95.1KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-15 English
Board Changes and Executive Restructuring 2 pages 732.7KB
Board/Management Information
2023-11-12 English
Final Director's Interest Notice - A. Vickery 2 pages 161.2KB
Director's Dealing
2023-11-12 English
Change of Director's Interest Notice - A. Vickery 4 pages 293.6KB
Director's Dealing
2023-11-09 English
Notification regarding unquoted securities - EMD 9 pages 34.9KB
Capital/Financing Update
2023-11-09 English
Application for quotation of securities - EMD 8 pages 30.5KB
Share Issue/Capital Change
2023-11-09 English
Section 708A(5)(e) Notice 1 page 90.6KB
Capital/Financing Update
2023-11-09 English
Results of General Meeting 2 pages 109.4KB
Declaration of Voting Results & Voting Rights Announcements
2023-10-30 English
Emyria Secures Ethics Endorsement for MDMA AP Application 3 pages 466.0KB
Regulatory Filings
2023-10-29 English
ASA Virtual Investor Summit Presentation October 2023 24 pages 6.6MB
Investor Presentation
2023-10-26 English
September 2023 Quarterly Activities Report and Appendix 4C 9 pages 2.1MB
Interim / Quarterly Report
2023-10-25 English
Change in substantial holding 3 pages 118.1KB
Major Shareholding Notification
2023-10-23 English
Health Canada Approval Received for MDMA Import 4 pages 727.5KB
Regulatory Filings
2023-10-18 English
Notice of Annual General Meeting/Proxy Form 29 pages 555.9KB
AGM Information
2023-10-12 English
Letter to Shareholders - Notice of Annual General Meeting 3 pages 280.4KB
AGM Information
2023-10-12 English
Change in substantial holding 3 pages 142.4KB
Major Shareholding Notification
2023-10-09 English
Change of Director's Interest Notice x 3 9 pages 406.9KB
Director's Dealing
2023-10-09 English
Application for quotation of securities - EMD 8 pages 30.5KB
Share Issue/Capital Change
2023-10-09 English
Notification of cessation of securities - EMD 5 pages 26.0KB
Regulatory Filings
2023-10-09 English
Section 708A(5)(e) Notice 1 page 90.4KB
Capital/Financing Update
2023-10-09 English
Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone 4 pages 784.2KB
Capital/Financing Update
2023-10-08 English
Completion of Entitlement Offer 3 pages 803.1KB
Capital/Financing Update
2023-10-04 English
Notification regarding unquoted securities - EMD 7 pages 29.3KB
Share Issue/Capital Change
2023-10-04 English
Application for quotation of securities - EMD 8 pages 30.4KB
Share Issue/Capital Change
2023-10-04 English
Notice of General Meeting/Proxy Form 24 pages 515.1KB
Proxy Solicitation & Information Statement
2023-09-27 English
Letter to Shareholders - Notice of General Meeting 3 pages 279.7KB
Proxy Solicitation & Information Statement
2023-09-27 English
Appendix 4G and Corporate Governance Statement 31 pages 544.9KB
Regulatory Filings
2023-09-26 English
2023 Annual Report 76 pages 6.7MB
Regulatory Filings
2023-09-26 English
Emyria Secures Local MDMA to Start PTSD Trial Dosing 4 pages 791.0KB
Capital/Financing Update
2023-09-20 English
Prospectus & Application Forms Available to Eligible Holders 1
Capital/Financing Update
2023-09-17 English
Application for quotation of securities - EMD 8 pages 30.5KB
Share Issue/Capital Change
2023-09-12 English
Application for quotation of securities - EMD 9 pages 33.3KB
Share Issue/Capital Change
2023-09-12 English
Emyria Completes Acquisition of the Pax Centre 3 pages 782.9KB
Capital/Financing Update
2023-09-12 English
Section 708A(5)(e) Notice 1 page 91.4KB
Capital/Financing Update
2023-09-12 English
Notice to Ineligible Shareholders of Entitlement Offer 1
Capital/Financing Update
2023-09-12 English
Prospectus 84 pages 964.0KB
Capital/Financing Update
2023-09-05 English
Strategic Update & Entitlement Offer Presentation 43 pages 9.6MB
Investor Presentation
2023-09-05 English
Becoming a substantial holder 3 pages 211.2KB
Major Shareholding Notification
2023-09-05 English
Notice to Optionholders - Non-Renounceable Entitlement Offer 1
Capital/Financing Update
2023-09-05 English
Notification of cessation of securities - EMD 5 pages 25.5KB
Share Issue/Capital Change
2023-09-04 English
Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer 6 pages 878.0KB
Capital/Financing Update
2023-09-03 English
Proposed issue of securities - EMD 17 pages 64.7KB
Capital/Financing Update
2023-09-03 English
Trading Halt 2 pages 745.5KB
Capital/Financing Update
2023-08-30 English
2023 Annual General Meeting - Key Dates 1 page 226.
AGM Information
2023-08-29 English
Appendix 4E Preliminary Financial Report 15 pages 513.6KB
Annual Report
2023-08-29 English
Notification regarding unquoted securities - EMD 9 pages 33.2KB
Share Issue/Capital Change
2023-08-22 English
Notification of cessation of securities - EMD 5 pages 25.8KB
Regulatory Filings
2023-08-22 English
Initial Director's Interest Notice - M. Kaushal 2 pages 189.9KB
Director's Dealing
2023-08-22 English
Final Director's Interest Notice - M. Callahan 2 pages 161.0KB
Director's Dealing
2023-08-22 English
Emyria Announces Strategic Board Transition 4 pages 816.6KB
Board/Management Information
2023-08-20 English
Change of Director's Interest Notice - A. Vickery 3 pages 234.0KB
Director's Dealing
2023-08-10 English
Change of Director's Interest Notice - S. Washer 3 pages 238.5KB
Director's Dealing
2023-08-09 English
Change of Director's Interest Notice - M. Winlo 3 pages 231.2KB
Director's Dealing
2023-08-08 English
Emyria Launches Ketamine-Assisted Therapy Program 6 pages 1.3MB
Regulatory Filings
2023-08-07 English
June 2023 Quarterly Activities Report and Appendix 4C 9 pages 864.6KB
Interim / Quarterly Report
2023-07-30 English
Emyria Recruits First Patient MDMA-Assisted Therapy Trial 6 pages 950.9KB
Regulatory Filings
2023-07-09 English
Presentation - Pax Acquisition and Company Update 47 pages 8.3MB
Investor Presentation
2023-07-05 English
Pax Centre Acquisition to Advance Psychedelic Therapies 8 pages 1.2MB
Capital/Financing Update
2023-07-02 English
Proposed issue of securities - EMD 5 pages 28.2KB
Capital/Financing Update
2023-07-02 English
Trading Halt 2 pages 388.4KB
Regulatory Filings
2023-06-28 English
Emyria Receives Ethics Approval for MDMA-assisted Therapy 4 pages 736.2KB
Regulatory Filings
2023-06-07 English
Notification regarding unquoted securities - EMD 9 pages 34.1KB
Share Issue/Capital Change
2023-05-09 English
Application for quotation of securities - EMD 8 pages 30.2KB
Capital/Financing Update
2023-05-09 English
Section 708A(5)(e) Notice 1 page 311.6KB
Capital/Financing Update
2023-05-09 English
Emyria Completes $2.5m Placement 3 pages 647.1KB
Capital/Financing Update
2023-04-30 English
Proposed issue of securities - EMD 6 pages 32.3KB
Capital/Financing Update
2023-04-30 English
March 2023 Quarterly Activities Report and Appendix 4C 8 pages 836.7KB
Interim / Quarterly Report
2023-04-27 English
Trading Halt 2 pages 718.6KB
Capital/Financing Update
2023-04-26 English
Emyria Unveils Highest Potency CBD Capsule for FDA Pathway 3 pages 643.8KB
Capital/Financing Update
2023-04-23 English
Emyria to Develop Psilocybin Therapy Care Model 4 pages 1.2MB
Regulatory Filings
2023-04-17 English
Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5 5 pages 1.2MB
Capital/Financing Update
2023-04-03 English
Strong Recruitment for EMD-RX5 Phase 3 Trial 4 pages 1.2MB
Capital/Financing Update
2023-03-22 English
Emyria Grows MDMA Asset for Neuro & Mental Health Therapy 3 pages 648.2KB
Capital/Financing Update
2023-03-19 English
Broker Briefing Presentation 26 pages 6.3MB
Investor Presentation
2023-03-15 English
Broker Briefing Biotech & Nutrition Investor Webinar 2 pages 536.2KB
Investor Presentation
2023-03-14 English
Emyria partners with PAX Centre for MDMA-assisted therapy 4 pages 638.5KB
Capital/Financing Update
2023-03-06 English
Company Secretary Change 2 pages 539.0KB
Board/Management Information
2023-02-28 English
Half Yearly Report and Accounts 31 pages 1.1MB
Interim / Quarterly Report
2023-02-26 English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 313.1KB
Capital/Financing Update
2023-02-26 English
Investor Presentation 30 pages 6.9MB
Investor Presentation
2023-02-23 English
Application for quotation of securities - EMD 8 pages 29.6KB
Capital/Financing Update
2023-02-22 English
Notification regarding unquoted securities - EMD 7 pages 28.5KB
Share Issue/Capital Change
2023-02-22 English
Change of Director's Interest Notice x 5 15 pages 406.6KB
Director's Dealing
2023-02-22 English
Emyria secures clinical-grade MDMA supply for Aust patients 3 pages 553.1KB
Capital/Financing Update
2023-02-12 English
Emyria expands MDMA programs following landmark TGA decision 11 pages 1.9MB
Regulatory Filings
2023-02-05 English
Change in substantial holding SW 3 pages 106.2KB
Major Shareholding Notification
2023-01-30 English
Appendix 4C - Quarterly 8 pages 747.6KB
Interim / Quarterly Report
2023-01-30 English
First dosing commenced for pivotal EMD-RX5 Phase 3 trial 4 pages 977.6KB
Capital/Financing Update
2023-01-29 English
Results of Meeting 3 pages 541.4KB
Declaration of Voting Results & Voting Rights Announcements
2023-01-24 English
Emyria receives $2.1M R&D tax incentive refund 2 pages 535.9KB
Capital/Financing Update
2023-01-11 English
Biotech Showcase San Francisco Presentation 54 pages 10.9MB
Investor Presentation
2023-01-09 English
Notification of cessation of securities - EMD 5 pages 25.4KB
Share Issue/Capital Change
2023-01-04 English